RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재 SCIE SCOPUS

      Subtype Is a Predictive Factor of Nonsentinel Lymph Node Involvement in Sentinel Node-Positive Breast Cancer Patients

      한글로보기

      https://www.riss.kr/link?id=A104425980

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      Purpose: This study aimed to identify the effect of breast cancersubtype on nonsentinel lymph node (NSLN) metastasis in patientswith a positive sentinel lymph node (SLN). Methods: Therecords of 104 early breast cancer patients with a positive SLNbetween April 2009 and September 2013 were retrospectivelyevaluated. All patients underwent axillary lymph node dissection.
      The effects of the tumor subtype (luminal A, luminal/HER2+, humanepidermal growth factor receptor 2 [HER2] overexpression,and triple-negative) and other clinicopathological factors onNSLN metastasis were examined by univariate and multivariatestatistical analyses. Results: Fifty of 104 patients (48%) exhibitedNSLN metastasis. Univariate and multivariate analyses revealedthat tumor size and the ratio of positive SLNs were significantrisk factors of NSLN metastasis in patients with a positive SLN.
      The rate of NSLN metastasis was higher in patients with luminal/HER2+ and HER2 overexpression subtypes than that in patientswith other subtypes in the univariate analysis (p<0.001). In themultivariate analysis, both patients with luminal/HER2+(p<0.006) and patients with HER2 overexpression (p<0.031)subtypes had a higher risk of NSLN metastasis than patientswith the luminal A subtype. Conclusion: Subtype classificationshould be considered as an independent factor when evaluatingthe risk of NSLN metastasis in patients with a positive SLN. Thisresult supports the development of new nomograms includingbreast cancer subtype to increase predictive accuracy.
      번역하기

      Purpose: This study aimed to identify the effect of breast cancersubtype on nonsentinel lymph node (NSLN) metastasis in patientswith a positive sentinel lymph node (SLN). Methods: Therecords of 104 early breast cancer patients with a positive SLNbetwe...

      Purpose: This study aimed to identify the effect of breast cancersubtype on nonsentinel lymph node (NSLN) metastasis in patientswith a positive sentinel lymph node (SLN). Methods: Therecords of 104 early breast cancer patients with a positive SLNbetween April 2009 and September 2013 were retrospectivelyevaluated. All patients underwent axillary lymph node dissection.
      The effects of the tumor subtype (luminal A, luminal/HER2+, humanepidermal growth factor receptor 2 [HER2] overexpression,and triple-negative) and other clinicopathological factors onNSLN metastasis were examined by univariate and multivariatestatistical analyses. Results: Fifty of 104 patients (48%) exhibitedNSLN metastasis. Univariate and multivariate analyses revealedthat tumor size and the ratio of positive SLNs were significantrisk factors of NSLN metastasis in patients with a positive SLN.
      The rate of NSLN metastasis was higher in patients with luminal/HER2+ and HER2 overexpression subtypes than that in patientswith other subtypes in the univariate analysis (p<0.001). In themultivariate analysis, both patients with luminal/HER2+(p<0.006) and patients with HER2 overexpression (p<0.031)subtypes had a higher risk of NSLN metastasis than patientswith the luminal A subtype. Conclusion: Subtype classificationshould be considered as an independent factor when evaluatingthe risk of NSLN metastasis in patients with a positive SLN. Thisresult supports the development of new nomograms includingbreast cancer subtype to increase predictive accuracy.

      더보기

      참고문헌 (Reference)

      1 Carey LA, "The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes" 13 : 2329-2334, 2007

      2 Reyal F, "The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma" 6 : e20297-, 2011

      3 Veronesi U, "Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes" 349 : 1864-1867, 1997

      4 Reynolds C, "Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer?" 17 : 1720-1726, 1999

      5 Gabos Z, "Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer" 24 : 5658-5663, 2006

      6 Rahusen FD, "Predictive factors for metastatic involvement of nonsentinel nodes in patients with breast cancer" 136 : 1059-1063, 2001

      7 Nos C, "Prediction of tumour involvement in remaining axillary lymph nodes when the sentinel node in a woman with breast cancer contains metastases" 90 : 1354-1360, 2003

      8 Schrenk P, "Prediction of non-sentinel lymph node status in breast cancer with a micrometastatic sentinel node" 92 : 707-713, 2005

      9 Degnim AC, "Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram" 190 : 543-550, 2005

      10 Reyal F, "Non-sentinel lymph node metastasis prediction in breast cancer with metastatic sentinel lymph node: impact of molecular subtypes classification" 7 : e47390-, 2012

      1 Carey LA, "The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes" 13 : 2329-2334, 2007

      2 Reyal F, "The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma" 6 : e20297-, 2011

      3 Veronesi U, "Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes" 349 : 1864-1867, 1997

      4 Reynolds C, "Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer?" 17 : 1720-1726, 1999

      5 Gabos Z, "Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer" 24 : 5658-5663, 2006

      6 Rahusen FD, "Predictive factors for metastatic involvement of nonsentinel nodes in patients with breast cancer" 136 : 1059-1063, 2001

      7 Nos C, "Prediction of tumour involvement in remaining axillary lymph nodes when the sentinel node in a woman with breast cancer contains metastases" 90 : 1354-1360, 2003

      8 Schrenk P, "Prediction of non-sentinel lymph node status in breast cancer with a micrometastatic sentinel node" 92 : 707-713, 2005

      9 Degnim AC, "Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram" 190 : 543-550, 2005

      10 Reyal F, "Non-sentinel lymph node metastasis prediction in breast cancer with metastatic sentinel lymph node: impact of molecular subtypes classification" 7 : e47390-, 2012

      11 Kohrt HE, "New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients" 8 : 66-, 2008

      12 Zhou W, "Molecular subtype classification is a determinant of non-sentinel lymph node metastasis in breast cancer patients with positive sentinel lymph nodes" 7 : e35881-, 2012

      13 Perou CM, "Molecular portraits of human breast tumours" 406 : 747-752, 2000

      14 Zhou WB, "Meta-analysis of sentinel lymph node biopsy at the time of prophylactic mastectomy of the breast" 54 : 300-306, 2011

      15 Cheang MC, "Ki67Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer" 101 : 736-750, 2009

      16 Sørlie T, "Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications" 98 : 10869-10874, 2001

      17 Chu KU, "Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection?" 229 : 536-541, 1999

      18 Moghaddam Y, "Comparison of three mathematical models for predicting the risk of additional axillary nodal metastases after positive sentinel lymph node biopsy in early breast cancer" 97 : 1646-1652, 2010

      19 Yin WJ, "Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients" 115 : 325-333, 2009

      20 Hwang RF, "Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer" 10 : 248-254, 2003

      21 Keshtgar MR, "Clinical role of sentinel-lymph-node biopsy in breast cancer" 3 : 105-110, 2002

      22 Weigelt B, "Breast cancer molecular profiling with single sample predictors: a retrospective analysis" 11 : 339-349, 2010

      23 Cheang MC, "Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype" 14 : 1368-1376, 2008

      24 Cserni G, "Axillary sentinel node and tumour-related factors associated with non-sentinel node involvement in breast cancer" 34 : 519-524, 2004

      25 Wolff AC, "American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer" 25 : 118-145, 2007

      26 Hammond ME, "American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer" 28 : 2784-2795, 2010

      27 Lyman GH, "American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer" 23 : 7703-7720, 2005

      28 Veronesi U, "A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer" 349 : 546-553, 2003

      29 Van Zee KJ, "A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy" 10 : 1140-1151, 2003

      30 Pal A, "A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive" 95 : 302-309, 2008

      더보기

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2023 평가예정 해외DB학술지평가 신청대상 (해외등재 학술지 평가)
      2020-01-01 평가 등재학술지 유지 (해외등재 학술지 평가) KCI등재
      2011-04-06 학술지명변경 외국어명 : Journal of Korean Breast Cancer -> Journal of Breast Cancer KCI등재
      2011-03-23 학술지명변경 외국어명 : Journal of Korean Breast Cancer -> 미등록 KCI등재
      2011-03-04 학술지명변경 한글명 : 한국유방암학회지 -> Journal of Breast Cancer KCI등재
      2011-01-01 평가 등재학술지 선정 (등재후보2차) KCI등재
      2010-01-01 평가 등재후보 1차 PASS (등재후보1차) KCI등재후보
      2008-01-01 평가 SCIE 등재 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 1.99 0.19 1.31
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      0.96 0.77 0.448 0.06
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼